Recent Developments: In June 2025, Eli Lilly and Company entered a high-value partnership with Camurus to develop long-acting GLP-1 and dual/triple incretin therapies using Camurus proprietary FluidCrystal technology, with deal terms that could reach up to $870 million
Risk of Thyroid C-cell Tumors Inform patients that liraglutide causes benign and malignant thyroid C-cell tumors in mice and rats and that the human relevance of this finding is unknown
No, both of these are strong GLP-1 medications that work in similar ways and should not be used together
Injection Bundles 10 WEEKLY LIPOTROPIC INJECTIONS Injection Bundles 10 WEEKLY LIPOTROPIC INJECTIONS Ten-week course of lipotropic injections better value for sustained fat-metabolism support
My thoughts werent constantly drawn to snacks or whats for dinner, and I found myself forgetting to eat on occasion, which I had literally never done in my entire life
However, individual response varies based on body composition, injection site, and metabolism
